Trastuzumab: unusual responses and toxicities

Area of Science:

• Oncology
• Pharmacology
• Pulmonology

Background:

• Trastuzumab is a cornerstone therapy for HER2-positive breast cancer in both metastatic and adjuvant settings.
• Its efficacy persists after disease progression, particularly when combined with chemotherapy.

Observation:

• While trastuzumab's cardiotoxicity is established, unusual pulmonary toxicities are increasingly recognized.
• This highlights a spectrum of potential adverse events associated with the drug.

Findings:

• The study reports cases demonstrating both the remarkable efficacy and the unusual toxicity of trastuzumab.
• These findings underscore the complex clinical profile of this important therapeutic agent.

Implications:

• Understanding these unusual toxicities is crucial for patient safety and treatment monitoring.
• Further research into the mechanisms and management of trastuzumab-induced pulmonary adverse events is warranted.